Asthma & Allergy Associates PC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$99,116	53
2024	Research	$11,791	3
2023	Research	$170,578	45
2022	Research	$46,533	23
2021	Research	$216,474	83
2020	Research	$63,834	37

Breakdown

Who paid Research payments · program years 2020–2025

Takeda Pharmaceuticals U.S.A., Inc. $363,343 180 payments
Teva Pharmaceuticals USA, Inc. $222,532 61 payments
GlaxoSmithKline, LLC. $22,450 3 payments

Studies the money was for Research payments · program years 2020–2025

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet $140,771 17 payments
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $112,488 49 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of Tak-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on A Gluten-Free Diet $72,379 47 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $66,170 3 payments
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $43,874 9 payments
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-Histaminergic Angioedema With Normal C1-Inhibitor (C1-Inh) and Acquired Angioedema (Aae) Due to C1-Inh Deficiency $32,875 38 payments
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-Histaminergic Angioedema With Normal C1-Inhibitor (C1-Inh) $30,839 21 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $22,450 3 payments
An Observational, Non-Interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (Empower Study) $16,646 19 payments
An Observational, Non-Interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (Empower Study) $15,698 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.